Atsuko Nakayama1, Hiroyuki Morita1, Tatsuyuki Sato1, Takuya Kawahara2, Norifumi Takeda1, Satoshi Kato3, Hiroshi Itoh4, Issei Komuro1. 1. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo. 2. Clinical Research Promotion Center, The University of Tokyo. 3. Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo. 4. Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine.
Abstract
AIM: We explored the superiority of small dense low-density lipoprotein cholesterol (sdLDL-C) as a marker for predicting not only the occurrence of cardiovascular (CV) events but also the need for laser treatment in patients with hypercholesterolemia and diabetic retinopathy. METHODS: We performed a sub-analysis of the intEnsive statin therapy for hyper-cholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY) study (n=5042), in which patients were assigned randomly to intensive or standard statin therapy targeting low-density lipoprotein cholesterol ＜70 mg/dl or 100-120 mg/dl. Using the survival analysis, the risks for CV events and the need for laser treatment were evaluated according to the lipids one year after registration. RESULTS: The patients were 63±11 years old. LDL-C and sdLDL-C levels were 98±25 and 32±14 mg/dl, respectively, one year after registration. The sdLDL-C level had a strong positive correlation with apolipoprotein B level (r=0.83 at registration). SdLDL-C was a sensitive marker for predicting CV events when comparing among the quartiles according to sdLDL-C levels (hazard ratios: HR for quartiles 1-4 were 1.0, 1.4, 1.6, and 2.5, respectively; p for trend ＜0.01). Also, sdLDL-C was a sensitive marker for predicting the need for laser treatment among lipids (log rank, p=0.009), especially in patients with elderly (≧65 yrs) and obesity (BMI ≧25 kg/m2). CONCLUSIONS: SdLDL-C is a sensitive target marker to predict cardiovascular events as well as the need for laser treatment in patients with hypercholesterolemia and diabetic retinopathy.
AIM: We explored the superiority of small dense low-density lipoprotein cholesterol (sdLDL-C) as a marker for predicting not only the occurrence of cardiovascular (CV) events but also the need for laser treatment in patients with hypercholesterolemia and diabetic retinopathy. METHODS: We performed a sub-analysis of the intEnsive statin therapy for hyper-cholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY) study (n=5042), in which patients were assigned randomly to intensive or standard statin therapy targeting low-density lipoprotein cholesterol ＜70 mg/dl or 100-120 mg/dl. Using the survival analysis, the risks for CV events and the need for laser treatment were evaluated according to the lipids one year after registration. RESULTS: The patients were 63±11 years old. LDL-C and sdLDL-C levels were 98±25 and 32±14 mg/dl, respectively, one year after registration. The sdLDL-C level had a strong positive correlation with apolipoprotein B level (r=0.83 at registration). SdLDL-C was a sensitive marker for predicting CV events when comparing among the quartiles according to sdLDL-C levels (hazard ratios: HR for quartiles 1-4 were 1.0, 1.4, 1.6, and 2.5, respectively; p for trend ＜0.01). Also, sdLDL-C was a sensitive marker for predicting the need for laser treatment among lipids (log rank, p=0.009), especially in patients with elderly (≧65 yrs) and obesity (BMI ≧25 kg/m2). CONCLUSIONS: SdLDL-C is a sensitive target marker to predict cardiovascular events as well as the need for laser treatment in patients with hypercholesterolemia and diabetic retinopathy.
Entities:
Keywords:
Diabetic retinopathy; Small dense low-density lipoprotein cholesterol; Statin
Authors: Edward K Duran; Aaron W Aday; Nancy R Cook; Julie E Buring; Paul M Ridker; Aruna D Pradhan Journal: J Am Coll Cardiol Date: 2020-05-05 Impact factor: 24.094
Authors: M D Davis; M R Fisher; R E Gangnon; F Barton; L M Aiello; E Y Chew; F L Ferris; G L Knatterud Journal: Invest Ophthalmol Vis Sci Date: 1998-02 Impact factor: 4.799
Authors: Janet L Leasher; Rupert R A Bourne; Seth R Flaxman; Jost B Jonas; Jill Keeffe; Kovin Naidoo; Konrad Pesudovs; Holly Price; Richard A White; Tien Y Wong; Serge Resnikoff; Hugh R Taylor Journal: Diabetes Care Date: 2016-09 Impact factor: 19.112
Authors: A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso Journal: Lancet Date: 2005-11-26 Impact factor: 79.321
Authors: J Elovson; J E Chatterton; G T Bell; V N Schumaker; M A Reuben; D L Puppione; J R Reeve; N L Young Journal: J Lipid Res Date: 1988-11 Impact factor: 5.922
Authors: Sepide Talebi; Mohammad Bagherniya; Stephen L Atkin; Gholamreza Askari; Hossein M Orafai; Amirhossein Sahebkar Journal: Lipids Health Dis Date: 2020-04-11 Impact factor: 3.876